-
Can We Fix the Broken Vaccine Supply Chain?
-
RGP CEO: Pandemic Accelerated Staffing Trends Already Underway
-
RGP CEO Kate Duchene Wins Top Industry Honor
-
The Pandemic Puts Business Continuity & Resilience to the Test
-
From Courtroom to Boardroom—Kate Duchene’s Path to CEO
-
Planning Tomorrow’s Workforce Today—Insights for HR Professionals
-
Orange County’s ‘Now of Work’ Can Lead California’s Future of Work
-
Nasdaq TradeTalks Interviews Tim Brackney on Building Community in Today’s Workforce
-
Tim Brackney Interviewed by Forbes on Post-Pandemic Work World
-
Forbes Names RGP to America’s Best Executive Recruiting Firms
-
How to Build Culture for Blended Workplaces
-
New Automotive Data Privacy Laws: Compliance How-To’s
Our Human Insights
Insights from our global thought leaders.
Solving ‘Vein-to-Vein’ Cell & Gene Therapy Supply Chain Challenges
The world’s COVID-19 vaccine distribution has shown the strengths and weaknesses of today’s supply chains. Healthcare companies pioneering cell and gene therapies—which rely on human cellular material—need to pay particular attention to lessons learned as they face unique supply chain challenges of their own. It all starts with planning.